Cantor Fitzgerald bolstered its healthcare and biotech equity research team with the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D. “Having two of the most highly regarded analysts in the biotechnology...
Search results for - CANTOR
Cantor ups Ardelyx to OW; PT to $10 ahead of October PDUFA date
Cantor Fitzgerald upgraded Ardelyx (NASDAQ:ARDX) to “overweight” from “neutral” and doubled its price target to $10 from $5, citing an upcoming PDUFA date of Oct. 17 for flagship drug, Xphozah, and higher sales...
Cantor cuts Aravive to neutral; PT to 25 cents on pipeline setback
Cantor Fitzgerald downgraded Aravive (NASDAQ:ARAV) to “neutral” from “overweight” and slashed its price target to 25 cents from $18 after the company indicated it might be forced to cease operations. The stock closed at...
Cantor starts Health Catalyst at OW; PT $16
Cantor Fitzgerald launched coverage of Health Catalyst (NASDAQ:HCAT) with an “overweight” rating and price target of $16, representing a 2024 enterprise value/revenue multiple of 2.3 times. The stock closed at $14.03 on...
Cantor starts Belite Bio at OW; PT $43
Cantor Fitzgerald launched coverage of Belite Bio (NASDAQ:BITR) with an “overweight” rating and a 12-month price target of $43. Belite listed its ADSs on NASDAQ in April 2022; they closed at $20.55 on July 27. Belite...
Cantor starts LifeMD at OW; PT $7
Cantor Fitzgerald initiated coverage of LifeMD (NASDAQ:LFMD) with an “overweight” rating and price target of $7. The stock closed at $3.53 on July 20. “We see LifeMD as an undervalued, below-the-radar growth story in...
Cantor starts AVITA Medical at OW; PT $23
Cantor Fitzgerald launched coverage of AVITA Medical (NASDAQ:RCEL) with an “overweight” rating and $23 target price. The stock closed at $15.71 on June 26. Avita is a regenerative medicine company commercializing its...
Cantor starts Acumen Pharma at OW; PT $13
Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with an “overweight” rating and 12-month price target of $13. The stock closed at $5.45 on May 17. Acumen is a neuro-Innovator leveraging its...
Cantor and Brookline change Hepion PTs to $28 and $74 post-split
Cantor Fitzgerald raised its price target for Hepion Pharmaceuticals (NASDAQ:HEPA) to $28 after a one-for-20 reverse stock split on May 10, and maintained an “overweight” rating. The stock closed at $6.81 on Friday. “We...
Cantor starts Disc Medicine at OW; PT $45
Cantor Fitzgerald launched coverage of Disc Medicine (NASDAQ:IRON) with an “overweight” rating and 12-month price target of $45. The stock closed at $32.24 on April 27. Disc Medicine is a clinical-stage...
